

STATISTICAL COMPENDIUM: MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT IN 2003 CONNECTICUT

LIST OF TABLES

OVERVIEW OF STUDY POPULATION

TABLE 1. OVERVIEW OF BENEFICIARY SELECTION CRITERIA FOR STUDY POPULATION

FOR ALL MEDICAID BENEFICIARIES

- TABLE 2. CHARACTERISTICS OF MEDICAID STUDY POPULATION BENEFICIARIES, BY BASIS OF ELIGIBILITY
- TABLE 3. ANNUAL MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFICIARY, BY BENEFICIARY CHARACTERISTIC
- TABLE 4. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC
- TABLE 5. AVERAGE MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BRAND STATUS AND BENEFICIARY CHARACTERISTIC
- TABLE 6. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY BRAND STATUS AND THERAPEUTIC CATEGORY
- TABLE 7. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY TOP 10 DRUG GROUP

FOR ALL NONDUAL BENEFICIARIES

- TABLE ND.2. CHARACTERISTICS OF MEDICAID STUDY POPULATION BENEFICIARIES, BY BASIS OF ELIGIBILITY
- TABLE ND.3. ANNUAL MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFICIARY, BY BENEFICIARY CHARACTERISTIC
- TABLE ND.4. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC
- TABLE ND.5. AVERAGE MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BRAND STATUS AND BENEFICIARY CHARACTERISTIC
- TABLE ND.6. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY BRAND STATUS AND THERAPEUTIC CATEGORY
- TABLE ND.7-7D. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY TOP 10 DRUG GROUP
- TABLE ND.8. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS, BY BENEFICIARY CHARACTERISTIC
- TABLE ND.9. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS, BY BRAND STATUS AND THERAPEUTIC CATEGORY
- TABLE ND.10-10D. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR TOP 10 DRUG GROUPS AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY TOP 10 DRUG GROUP
- TABLE ND.11. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D AMONG NONDUALS, BY BENEFICIARY CHARACTERISTIC
- TABLE ND.12. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D AMONG NONDUALS PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC
- TABLE ND.13. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D FOR SELECTED DRUG CATEGORIES AMONG NONDUALS

FOR DUAL ELIGIBLE BENEFICIARIES

TABLE D.2. CHARACTERISTICS OF MEDICAID STUDY POPULATION BENEFICIARIES, BY BASIS OF ELIGIBILITY

TABLE D.3. ANNUAL MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFICIARY, BY BENEFICIARY CHARACTERISTIC

TABLE D.4. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT *PER BENEFIT MONTH*, BY BENEFICIARY CHARACTERISTIC

TABLE D.5. AVERAGE MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BRAND STATUS AND BENEFICIARY CHARACTERISTIC

TABLE D.6. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY BRAND STATUS AND THERAPEUTIC CATEGORY

TABLE D.7-7D. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY TOP 10 DRUG GROUP

TABLE D.8. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS, BY BENEFICIARY CHARACTERISTIC

TABLE D.9. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS, BY BRAND STATUS AND THERAPEUTIC CATEGORY

TABLE D.10-10D. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR TOP 10 DRUG GROUPS AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY TOP 10 DRUG GROUP

TABLE D.11. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D AMONG DUALS, BY BENEFICIARY CHARACTERISTIC

TABLE D.12. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D AMONG DUALS PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC

TABLE D.13. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D FOR SELECTED DRUG CATEGORIES AMONG DUALS

SUPPLEMENTAL TABLES

SUPPLEMENTAL TABLE 1. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES

SUPPLEMENTAL TABLE 1A. MEDICAID PHARMACY REIMBURSEMENT FOR DISABLED DUAL ELIGIBLE BENEFICIARIES UNDER AGE 65

SUPPLEMENTAL TABLE 1B. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES AGE 65 AND OLDER

SUPPLEMENTAL TABLE 1C. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES AGE 65 TO 74

SUPPLEMENTAL TABLE 1D. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES AGE 75 TO 84

SUPPLEMENTAL TABLE 1E. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES AGE 85 AND OLDER

APPENDIX TABLES

APPENDIX TABLE A.1. CHARACTERISTICS OF MEDICAID BENEFICIARIES WITH AT LEAST ONE MONTH OF PHARMACY BENEFIT COVERAGE, BY BASIS OF ELIGIBILITY, NONDUAL BENEFICIARIES

APPENDIX TABLE A.2. MEDICAID BENEFICIARIES AND THEIR BENEFIT MONTHS WITH OR WITHOUT FEE-FOR-SERVICE PHARMACY BENEFITS, NONDUAL BENEFICIARIES

APPENDIX TABLE A.3. CHARACTERISTICS OF MEDICAID BENEFICIARIES WITH AT LEAST ONE MONTH OF PHARMACY BENEFIT COVERAGE, BY BASIS OF ELIGIBILITY, DUAL ELIGIBLE BENEFICIARIES

APPENDIX TABLE A.4. MEDICAID BENEFICIARIES AND THEIR BENEFIT MONTHS WITH OR WITHOUT FEE-FOR-SERVICE PHARMACY BENEFITS, DUAL ELIGIBLE BENEFICIARIES

TABLE 1
OVERVIEW OF BENEFICIARY SELECTION CRITERIA FOR STUDY POPULATION
CONNECTICUT, 2003

Inclusion Criteria (2003)	Number of Dual and Non-dual Eligible Beneficiaries (Cell)	Number of Dual Eligible Beneficiaries (Cell) ^g	Number of Non-dual Eligible Beneficiaries (Cell)
1. Beneficiaries who were eligible for Medicaid during at least one month ^a	511,681 (A)	96,731 (E)	414,950 (I)
2. Beneficiaries who had Medicaid pharmacy benefits during at least one month ^b	495,229 (B)	80,573 (F)	414,656 (J)
3. Beneficiaries who had fee-for-service pharmacy benefit coverage during at least one month ^{c, d, e}	213,999 (C)	80,380 (G)	133,619 (K)
4. Beneficiaries who were all-year nursing facility residents ^f	19,877 (D)	18,627 (H)	1,250 (L)

Source: Data for this table are from the MAX 2003 file for Connecticut, released by CMS in 05/2007. This table was produced on 11/01/2007.

- a. MAX data element "Eligible Months Count" was used to determine an individual's Medicaid eligibility. All individuals who had a value greater than zero were considered as beneficiaries and counted in Cell A.
- b. Counts in Cell B were obtained by excluding from Cell A beneficiaries who never had pharmacy benefit coverage during their Medicaid enrollment in 2003 (based on MAX data element "Eligible Restricted Benefits Flag").
- c. Cell C represents the study population for Tables 2 through 7. Cell C was obtained by excluding from Cell B beneficiaries who were in managed care (MC) plans that included prescription drugs in their capitated benefit package during all months of Medicaid eligibility in 2003, because the MAX files do not include separate prescription drug claims for those beneficiaries. MC plans include health maintenance organizations (HMOs), prepaid health plans (PHPs), or other MC organizations that provide health care benefits under capitation arrangements. Beneficiaries included in the study population are those who were in fee-for-service or primary care case management (PCCM) programs. In addition, beneficiaries in selected states in which prescription drug benefits were not covered in the capitated benefit package in MC or PHP plans are also included (see footnote e for a list of these states). In those states, if a beneficiary spent part of the year in fee-for-service, PCCM, or in a PHP or MC plan in which drugs were not included in the capitation, and spent part of the year in a PHP or MC plan in which drugs were capitated, only the months with fee-for-service pharmacy benefits are included in the tables. For example, if a beneficiary was in an MC plan that did not include prescription drugs in the capitation for 3 months of the year, and in a PHP with capitated drug coverage for the remaining 9 months, only the 3 months would be counted toward the number of benefit months associated with the beneficiary. Therefore, benefit months included represent the benefit months with fee-for-service pharmacy benefits.
- d. The total Medicaid pharmacy reimbursement for Connecticut in 2003 was \$397,842,148, of which \$124,101 was excluded from our analysis because those claims were made for beneficiaries who were outside the study population or took place during months that were excluded from the analysis.
- e. Enrollees in prepaid health plans (PHP) or managed care (MC) plans that did not provide a pharmacy benefit are treated as having fee-for-service pharmacy benefit coverage. There were 19 states in 2003 that had PHPs that did not include a pharmacy benefit: AL, AR, CA, CO, FL, GA, IA, KY, MA, MI, NY, OR, PA, SD, TN, TX, UT, WA, and WI. In addition, there were 7 states in which MC plans did not provide a pharmacy benefit: DE, IA, NE, NY, TX, UT, and WV. These lists were constructed from the CMS 2003 Medicaid Managed Care Enrollment Report [<http://www.cms.hhs.gov/MedicaidDataSourcesGenInfo/Downloads/rmmcer02.pdf>] and by checking PHP and MC pharmacy coverage as necessary through state, PHP, and MC web sites. As a further check, we analyzed prescription drug claims for those reported as being in managed care all year in the MAX files (see Appendix Tables A.1 and A.3) to determine whether the annual number and cost of claims per person for those beneficiaries were comparable to those of beneficiaries reported as being in fee-for-service all year. If they were, that provided additional evidence that prescription drugs were not included in the managed care capitated benefit package.
- f. Cell H represents the study population for Tables D.8 through D.10D. Cell L represents the study population for Tables ND.8 through ND.10D. All-year nursing facility residents are the beneficiaries who resided in nursing facilities throughout their enrollment in 2003. These beneficiaries were identified by comparing the number of months during which the MAX files contained at least one claim from nursing facilities to the number of Medicaid eligible months. If the former is greater than or equal to the latter, the beneficiary was considered an all-year resident. If the former is less than the latter but not equal to zero, the beneficiary was considered a part-year resident. Part-year residents are treated separately because they are likely to be short-term residents and the level and pattern of their pharmacy benefit use may differ substantially from longer-term residents. The number of part-year residents and their benefit months are presented in footnotes to Tables D.8 through D.10D and ND.8 through ND.10D. Residents of mental hospitals for the aged, inpatient psychiatric facilities for individuals under age 21, or intermediate care facilities for the mentally retarded are not counted as nursing facility residents in the nursing facility tables.

g. Pharmacy benefit use and reimbursement among full dual eligible beneficiaries are presented in Tables D.2 through D.7D, Tables D.11 through D.13, and Supplemental Tables 1 through 1E corresponding to the sample of beneficiaries in Cell G. To determine Medicaid-Medicare dual eligibility status, two MAX data elements ("Eligible Medicare Crossover Code -- Annual New Values" and "Eligible Restricted Benefits Flag") were used in combination. The dual eligible tables include all dual eligible benefit months in which the beneficiary had a fee-for-service pharmacy benefit.

Beneficiaries represented in Cell G, the dual study population, include all dual eligible beneficiaries who had a fee-for-service pharmacy benefit at least during one month in 2003. The dual eligible tables include all dual eligible benefit months in which the beneficiary had a fee-for-service pharmacy benefit.

Characteristics of non-dual eligible beneficiaries represented by Cell J are shown in Appendix Table A.1 and characteristics of non-dual eligible beneficiaries and their benefit months included in Cell J but excluded from Cell K are shown in Appendix Table A.2. Characteristics of dual eligible beneficiaries represented by Cell F are shown in Appendix Table A.3, and characteristics of dual eligible beneficiaries and their benefit months included in Cell F but excluded from Cell G are shown in Appendix Table A.4.

Bene(s) = beneficiary (or beneficiaries); CMS = Centers for Medicare & Medicaid Services; HMO = health maintenance organization; MAX = Medicaid Analytic Extract; MC = managed care; PCCM = primary care case management; PHP = prepaid health plan.

TABLE 2
 CHARACTERISTICS OF MEDICAID STUDY POPULATION BENEFICIARIES, BY BASIS OF ELIGIBILITY^{a,b}
 CONNECTICUT, 2003

Beneficiary Characteristics	Number of Beneficiaries							Number of Benefit Months						
	All	Aged	Disabled	Adults	Children	Other/ Unknown	0	All	Aged	Disabled	Adults	Children	Other/ Unknown	
All	213,999	52,301	59,134	34,312	68,252	0	1,436,122	543,539	632,303	88,997	171,283	0		
Age														
5 and younger	24,630	0	0	5	24,625	0	56,809	0	0	12	56,797	0		
6-14	26,037	0	1	7	26,029	0	67,208	0	12	20	67,176	0		
15-20	17,974	1	862	1,512	15,599	0	53,367	6	7,447	3,439	42,475	0		
21-44	55,124	46	24,411	28,712	1,955	0	336,492	385	260,694	70,676	4,737	0		
45-64	37,619	118	33,524	3,945	32	0	375,896	1,024	361,002	13,788	82	0		
65-74	16,888	16,435	335	117	1	0	182,347	178,251	3,136	957	3	0		
75-84	17,988	17,975	1	12	0	0	189,232	189,128	12	92	0	0		
85 and older	17,728	17,726	0	2	0	0	174,758	174,745	0	13	0	0		
Unknown	11	0	0	0	11	0	13	0	0	0	13	0		
Gender														
Female	129,608	38,294	30,952	25,903	34,459	0	888,041	401,602	335,614	65,521	85,304	0		
Male	84,391	14,007	28,182	8,409	33,793	0	548,081	141,937	296,689	23,476	85,979	0		
Unknown	0	0	0	0	0	0	0	0	0	0	0	0		
Race														
White	113,692	37,797	33,675	15,462	26,758	0	860,864	386,465	363,982	41,126	69,291	0		
African American	40,021	6,095	11,280	6,888	15,758	0	243,208	66,389	118,829	18,427	39,563	0		
Other/unknown	60,286	8,409	14,179	11,962	25,736	0	332,050	90,685	149,492	29,444	62,429	0		
Use of Nursing Facilities^c														
Entire year	19,877	17,638	2,217	1	21	0	203,340	178,759	24,343	3	235	0		
Part year	9,295	7,102	2,157	19	17	0	92,067	69,251	22,567	136	113	0		
None	184,827	27,561	54,760	34,292	68,214	0	1,140,715	295,529	585,393	88,858	170,935	0		
Maintenance Assistance Status														
Cash	38,667	5,821	14,345	6,281	12,220	0	269,037	65,786	161,791	14,545	26,915	0		
Medically needy	41,401	12,946	25,470	903	2,082	0	415,022	135,797	270,148	2,822	6,255	0		
Poverty-related	34,087	1,064	1,369	5,904	25,750	0	99,957	11,229	14,566	11,385	62,777	0		
Other/unknown	99,844	32,470	17,950	21,224	28,200	0	652,106	330,727	185,798	60,245	75,336	0		
Dual Medicare Status^d														
Full dual, all year	75,023	46,142	27,151	1,693	37	0	793,446	479,326	298,954	14,904	262	0		
Full dual, part year	5,357	2,547	2,773	36	1	0	59,793	28,591	30,813	377	12	0		
Non-dual, all year	133,619	3,612	29,210	32,583	68,214	0	582,883	35,622	302,536	73,716	171,009	0		
Managed Care (MC) Status														
Fee-for-service (FFS) all year	131,585	52,281	58,286	9,220	11,798	0	1,246,128	543,423	627,295	33,035	42,375	0		
FFS part year, with Rx claims	15,272	16	670	6,244	8,342	0	43,538	94	4,296	16,790	22,358	0		
FFS part year, no Rx claims	67,142	4	178	18,848	48,112	0	146,456	22	712	39,172	106,550	0		

Source: Data for this table are from the MAX 2003 file for Connecticut, released by CMS in 05/2007. This table was produced on 11/01/2007.

a. Table 2 includes the beneficiaries represented by Cell C of Table 1. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services. The total includes some beneficiaries with unknown basis of eligibility and some whose age categories are not consistent with basis of eligibility.

c. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.

d. The "Full dual, all year" group includes beneficiaries who had Medicare coverage as well as Medicaid fee-for-service pharmacy benefits during all months of Medicaid enrollment in 2003. The "Full dual, part year" group includes beneficiaries who had such benefits for some, but not all, months of their enrollment. The "Non-dual, all year" group includes beneficiaries who were never dually eligible. Refer to footnote g of Table 1 for more information about how we determined dual eligibility status.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; FFS = fee-for-service pharmacy benefit; MAX = Medicaid Analytic Extract; MC = managed care; Rx = pharmacy benefit.

TABLE 3
ANNUAL MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFICIARY, BY BENEFICIARY CHARACTERISTIC^{a, b}
CONNECTICUT, 2003

Beneficiary Characteristics	Percentage with at Least One Rx	Mean Number of Rx	Mean Rx \$	\$ per Rx	Mean \$, All Medicaid FFS \$ ^c		Rx \$ as a Percentage of All Medicaid FFS \$ ^d		Number of Beneficiaries
					\$1,859	\$71	\$13,485	13.8 %	
All	55.4 %	26.2	\$1,859	\$71	\$13,485	13.8 %	213,999		
Age									
5 and younger	13.3	0.4	23	55	2,428	0.9	24,630		
6-14	13.5	0.9	68	75	1,707	4.0	26,037		
15-20	22.0	2.1	163	78	3,015	5.4	17,974		
21-44	51.0	19.4	1,776	92	11,382	15.6	55,124		
45-64	85.1	49.3	3,953	80	20,805	19.0	37,619		
65-74	89.0	47.2	2,965	63	16,865	17.6	16,888		
75-84	90.8	51.6	2,913	56	24,863	11.7	17,988		
85 and older	92.1	49.5	2,448	49	33,017	7.4	17,728		
Unknown	0.0	0.0	0	0	0	0.0	11		
Basis of Eligibility^e									
Aged	90.7	49.5	2,774	56	25,121	11.0	52,301		
Disabled	88.7	48.4	4,077	84	22,920	17.8	59,134		
Adults	24.6	2.6	215	83	2,025	10.6	34,312		
Children	15.0	0.8	61	73	2,156	2.8	68,252		
Unknown	0.0	0.0	0	0	0	0.0	0		
Gender									
Female	58.4	28.5	1,888	66	13,470	14.0	129,608		
Male	50.8	22.6	1,814	80	13,509	13.4	84,391		
Unknown	0.0	0.0	0	0	0	0.0	0		
Race									
White	64.3	34.4	2,362	69	19,029	12.4	113,692		
African American	48.5	19.9	1,539	77	9,283	16.6	40,021		
Other/unknown	43.2	14.8	1,122	76	5,821	19.3	60,286		
Use of Nursing Facilities^f									
Entire year	94.4	65.7	3,741	57	49,708	7.5	19,877		
Part year	95.8	62.8	3,851	61	32,649	11.8	9,295		
None	49.2	20.1	1,556	78	8,626	18.0	184,827		
Maintenance Assistance Status									
Cash	57.8	27.7	2,116	76	12,499	16.9	38,667		
Medically needy	84.1	41.3	3,154	76	11,382	27.7	41,401		
Poverty related	18.1	1.9	145	78	2,368	6.1	34,087		
Other/unknown	55.3	27.6	1,807	66	18,535	9.7	99,844		

Source: Data for this table are from the MAX 2003 file for Connecticut, released by CMS in 05/2007. This table was produced on 11/01/2007.

- a. Table 3 includes beneficiaries represented by Cell C of Table 1.
 - b. The Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
 - c. In seven states (DE, IA, NE, NY, TX, UT, and WV) the expenditures in this column include only Rx drug expenditures for those enrolled in capitated managed care plans, and not expenditures for other services covered by the plans or long-term-care services not covered by the plans. As a result, the amounts shown in this column for all Medicaid fee-for-service expenditures are lower than they would otherwise be.
 - d. In seven states (DE, IA, NE, NY, TX, UT, and WV) the Rx share of expenditures for all Medicaid services shown in this column is higher than it would be if all expenditures for these other services, including services provided in capitated managed care plans and long-term-care services, were included.
 - e. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services.
 - f. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.
- Bene(s) = beneficiary (or beneficiaries); CMS = Centers for Medicare & Medicaid Services; FFS = fee-for-service; MAX = Medicaid Analytic Extract; OTC = over-the-counter; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE 4
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC^{a, b}
 CONNECTICUT, 2003

Beneficiary Characteristics	Number of Rx, Percentage with:										Beneficiaries	Number
	Mean Number of Rx	Mean Rx \$	Percentage of All Medicaid FFS \$ ^c	None	More than 0, but 1 or Less	More than 1, but 2 or Less	More than 2, but 5 or Less	More than 5, but 10 or Less	More than 10	Mean \$, All Medicaid FFS \$ ^d		
All	3.9	\$277	13.8 %	44.6 %	14.6 %	7.2 %	16.4 %	12.9 %	4.3 %	\$2,010	213,999	1,436,122
Age												
5 and younger	0.2	10	0.9	86.7	11.1	1.4	0.6	0.1	0.0	1,053	24,630	56,809
6-14	0.4	26	4.0	86.5	9.6	2.0	1.5	0.3	0.1	661	26,037	67,208
15-20	0.7	55	5.4	78.0	15.3	3.0	2.9	0.7	0.2	1,015	17,974	53,367
21-44	3.2	291	15.6	49.0	18.8	7.8	13.5	8.0	2.9	1,865	55,124	336,492
45-64	4.9	396	19.0	14.9	15.6	10.8	27.5	22.6	8.6	2,082	37,619	375,896
65-74	4.4	275	17.6	11.0	17.2	12.2	29.4	22.9	7.2	1,562	16,888	182,347
75-84	4.9	277	11.7	9.2	12.9	10.3	30.3	28.4	9.0	2,364	17,988	189,232
85 and older	5.0	248	7.4	7.9	10.1	9.7	33.1	31.5	7.6	3,349	17,728	174,758
Unknown	0.0	0	0.0	100.0	0.0	0.0	0.0	0.0	0.0	0	11	13
Basis of Eligibility^e												
Aged	4.8	267	11.0	9.3	13.4	10.7	31.0	27.7	8.0	2,417	52,301	543,539
Disabled	4.5	381	17.8	11.3	19.8	11.8	27.8	21.1	8.1	2,144	59,134	632,303
Adults	1.0	83	10.6	75.4	14.1	4.4	4.4	1.6	0.3	781	34,312	88,997
Children	0.3	24	2.8	85.0	11.2	2.0	1.4	0.3	0.1	859	68,252	171,283
Unknown	0.0	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0	0	0
Gender												
Female	4.2	276	14.0	41.6	14.5	7.4	17.6	14.2	4.7	1,966	129,608	888,041
Male	3.5	279	13.4	49.2	14.8	6.9	14.6	11.0	3.5	2,080	84,391	548,081
Unknown	0.0	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0	0	0
Race												
White	4.5	312	12.4	35.7	13.4	7.6	19.6	17.5	6.3	2,513	113,692	860,864
African American	3.3	253	16.6	51.5	15.9	6.8	13.6	9.4	2.7	1,528	40,021	243,208
Other/unknown	2.7	204	19.3	56.8	16.1	6.7	12.2	6.7	1.5	1,057	60,286	332,050
Use of Nursing Facilities^f												
Entire year	6.4	366	7.5	5.6	5.6	6.7	28.5	38.6	15.0	4,859	19,877	203,340
Part year	6.3	389	11.8	4.2	8.0	7.5	30.9	35.2	14.1	3,296	9,295	92,067
None	3.2	252	18.0	50.8	15.9	7.3	14.4	9.1	2.6	1,398	184,827	1,140,715
Maintenance Assistance Status												
Cash	4.0	304	16.9	42.2	16.5	7.9	17.0	12.3	4.1	1,796	38,667	269,037
Medically needy	4.1	315	27.7	15.9	19.3	12.0	27.7	18.9	6.1	1,135	41,401	415,022
Poverty related	0.6	50	6.1	81.9	12.5	2.6	2.2	0.6	0.1	808	34,087	99,957
Other/unknown	4.2	277	9.7	44.7	12.6	6.5	16.3	14.9	4.9	2,838	99,844	652,106

All Medicaid Beneficiaries

Table 4

Source: Data for this table are from the MAX 2003 file for Connecticut, released by CMS in 05/2007. This table was produced on 11/01/2007.

- a. Table 4 includes the beneficiaries represented by Cell C of Table 1. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.
- b. The Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
- c. In seven states (DE, IA, NE, NY, TX, UT, and WV) the expenditures in this column include only Rx drug expenditures for those enrolled in capitated managed care plans, and not expenditures for other services covered by the plans or long-term-care services not covered by the plans. As a result, the amounts shown in this column for all Medicaid fee-for-service expenditures are lower than they would otherwise be.
- d. In seven states (DE, IA, NE, NY, TX, UT, and WV) the Rx share of expenditures for all Medicaid services shown in this column is higher than it would be if all expenditures for these other services, including services provided in capitated managed care plans and long-term-care services, were included.
- e. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services.
- f. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; FFS = fee-for-service; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

Source: Data for this table are from the MAX 2003 file for Connecticut, released by CMS in 05/2007. This table was produced on 11/01/2007.

- a. Table 5 includes the beneficiaries represented by Cell C of Table 1. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.
- b. The Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
- c. Brand-name drugs, sometimes called "innovator single-source drugs," are drugs whose patents have not yet expired. Off-patent brand-name drugs, sometimes called "innovator multiple-source drugs," are brand-name drugs whose patents have expired. Generic drugs, sometimes called "non-innovator multiple-source drugs," are off-patent drugs manufactured and sold by companies other than the original patent holder. In Connecticut, 0.2 percent of drug claims have missing values for brand status. Thus, the sum of the three groups in this table may be smaller than all combined. For information about this classification method, see Wolters Kluwer Health, <http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615> (October 26, 2007)
- d. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services.
- e. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.

CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE 6
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY BRAND STATUS AND THERAPEUTIC CATEGORY^{a, b, c, d}
 CONNECTICUT, 2003

Therapeutic Category	Number of Rx per Benefit Month Among Users			\$ per Benefit Month Among Users			\$ per Rx			Users ^e							
	Total	Patented Brand-Name	Generic Brand-Name	Total	Patented Brand-Name	Generic Brand-Name	Total	Patented Brand-Name	Generic Brand-Name	Total Rx \$	Number of Users	Percentage of All Beneficiaries	As a Percentage of All Beneficiaries	Number of Benefit Months			
															Off-Patent	Generic	Off-Patent
Anti-infective Agents	0.4	0.2	0.0	0.2	\$53	\$48	\$0	\$4	\$141	\$230	\$85	\$27	246,538	\$34,805,809	63,545	29.7 %	660,206
Biologics	0.1	0.1	0.0	0.0	45	11	0	34	412	140	1,197	1,031	1,394	573,785	1,147	0.5	12,648
Antineoplastic Agents	0.5	0.2	0.0	0.3	132	104	1	27	274	505	182	100	20,146	5,510,407	4,039	1.9	41,690
Endocrine/Metabolic Drugs	0.9	0.4	0.1	0.4	45	35	2	8	48	80	19	20	484,903	23,272,631	49,003	22.9	520,059
Cardiovascular Agents	1.6	0.6	0.0	1.0	66	47	1	18	40	73	42	19	1,173,597	47,276,571	66,736	31.2	720,526
Respiratory Agents	0.7	0.4	0.0	0.3	41	33	2	6	57	78	72	23	350,302	19,949,871	47,043	22.0	491,894
Gastrointestinal Agents	0.7	0.4	0.0	0.3	72	58	0	13	97	134	73	43	369,646	35,748,028	46,223	21.6	498,428
Genitourinary Agents	0.5	0.4	0.0	0.1	34	33	0	2	65	76	38	18	90,827	5,868,706	15,821	7.4	170,526
CNS Drugs	1.7	0.9	0.0	0.7	152	126	4	21	91	136	124	30	1,228,653	111,801,892	69,290	32.4	737,009
Stimulants/Anti-obesity/Anorexia	0.6	0.3	0.0	0.2	52	40	3	9	84	116	83	38	14,597	1,229,574	2,487	1.2	23,531
Miscellaneous Psychological/Neurological Agents	0.7	0.7	0.0	0.0	106	106	0	0	148	149	0	33	44,906	6,634,729	5,931	2.8	62,338
Analgesics and Anesthetics	0.8	0.4	0.0	0.4	61	52	2	8	78	147	86	19	484,776	37,815,559	58,837	27.5	619,983
Neuromuscular Agents	1.2	0.5	0.1	0.5	77	60	3	14	67	112	49	25	493,999	33,157,053	39,370	18.4	428,621
Nutritional Products	0.6	0.0	0.0	0.6	13	1	1	11	21	66	15	19	107,116	2,205,855	17,230	8.1	173,249
Hematological Agents	0.9	0.2	0.1	0.6	70	61	1	7	81	267	20	13	194,162	15,690,104	21,241	9.9	224,984
Topical Products	0.5	0.2	0.0	0.2	22	15	1	5	46	69	52	23	269,091	12,310,019	52,682	24.6	566,992
Miscellaneous Products	0.4	0.2	0.0	0.1	84	67	10	7	238	372	271	51	12,935	3,080,251	3,574	1.7	36,812
Unknown Therapeutic Category	0.3	0.0	0.0	0.0	21	0	0	0	84	0	0	0	9,369	787,203	3,632	1.7	37,338
TOTAL NO. OF RX AND RX \$	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	5,596,957	397,718,047	n.a.	n.a.	n.a.

Source: Data for this table are from the MAX 2003 file for Connecticut, released by CMS in 05/2007. This table was produced on 11/01/2007.

a. Table 6 includes the beneficiaries represented by Cell C of Table 1. A beneficiary who used drugs from two or more categories was counted as a user for each category. Therefore, the sum of users across categories may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. For information about these therapeutic categories, see Wolters Kluwer Health, <http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615> (October 26, 2007).

d. Brand-name drugs, sometimes called "innovator single-source drugs," are drugs whose patents have not yet expired. Off-patent brand-name drugs, sometimes called "innovator multiple-source drugs," are brand-name drugs whose patents have expired. Generic drugs, sometimes called "non-innovator multiple-source drugs," are off-patent drugs manufactured and sold by companies other than the original patent holder. In Connecticut, 0.2 percent of drug claims have missing values for brand status. Thus, the sum of the three groups in this table may be smaller than all prescriptions combined.

For information about this classification method, see Wolters Kluwer Health, <http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615> (October 26, 2007).

e. A user is a beneficiary who had at least one prescription filled in a given therapeutic category during 2003.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; CNS = Central Nervous System; MAX = Medicaid Analytic Extract; n.a. = not applicable; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE 7
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY TOP 10 DRUG GROUP^{a, b, c}
 CONNECTICUT, 2003

Top 10 Drug Groups	Users			Among Users		
	Total Medicaid Rx \$	Number of All Beneficiaries	As a Percentage	Number of Benefit Months	Number of Rx per Benefit Month	Rx \$ per Benefit Month
ANTIPSYCHOTICS	\$71,891,069	47,420	22.2 %	522,342	0.9	\$158
ANTIDEPRESSANTS	30,983,178	65,110	30.4	699,552	0.7	62
ULCER DRUGS	30,152,876	44,198	20.7	480,630	0.6	109
ANTICONVULSANT	28,356,348	37,365	17.5	410,378	0.9	78
ANTIVIRAL	23,432,382	9,831	4.6	106,169	0.5	434
ANALGESICS - Narcotic	21,936,477	58,001	27.1	620,684	0.4	80
ANTIHYPERTENSIVE	18,118,866	28,596	13.4	319,962	0.6	92
ANTIDIABETIC	16,347,916	37,954	17.7	415,548	0.7	59
ANTIASTHMATIC	12,594,799	45,747	21.4	482,149	0.4	64
ANALGESICS - ANTI-INFLAMMATORY	12,001,420	40,391	18.9	443,828	0.4	77
Total	265,815,331	414,613		4,501,242	n.a.	n.a.

Source: Data for this table are from the MAX 2003 file for Connecticut, released by CMS in 05/2007. This table was produced on 11/01/2007.

a. Table 7 includes the beneficiaries represented by Cell C of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2003. A beneficiary who used drugs from two or more groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2003. For information about these drug groups, see Wolters Kluwer Health, <http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615> (October 26, 2007).

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.